In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease. Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — ...
Getting help for depression can be like purgatory. Setting aside for a moment the stigma and other barriers to seeking treatment in the first place, finding the right combination of medication and/or therapy can be a months- or years-long process of trial and error. And for about one third of people, nothing seems to work.Today we're talking with Dr. Leanne Williams, the founding director of the Stanford Center for Precision Mental Health and Wellness and Vincent V.C. Woo Professor in the Sta...
Today, we're talking with Stanford neuro-oncologist, Michelle Monje. This is actually the third time we've had Michelle on the show, in part because she's been a pioneer of three exciting frontiers in neuroscience — so far! This week, we're going to talk about cancer neuroscience. Michelle founded this new field with her discovery that deadly brain tumors not only link up physically with the healthy brain tissue surrounding them, but the cancers actually need the brain's electrical activ...
This week on From Our Neurons to Yours, we're talking about using new techniques for growing human brain tissue in the lab to solve a rare neurological disorder.Host Nicholas Weiler sits down with Sergiu Pasca an innovative Stanford scientist who has developed groundbreaking technologies to grow human brain tissue in the lab, creating "organoids" and "assembloids" that model brain disorders like autism and schizophrenia. Pasca describes the process of turning patient skin cells into embr...
Today, we're going to talk about virtual reality and how it could be used to treat depression. We're talking with psychiatrist Kim Bullock, the founding director of Stanford's Neurobehavioral Clinic and Virtual Reality & Immersive Technologies (VRIT) program. Dr. Bullock — a physician certified in Neuropsychiatry, Psychiatry, and Lifestyle Medicine — calls herself a "radical behaviorist." Like other practitioners of cognitive behavioral therapy (CBT), she sees the troublesome thought...
The skin is full of contradictions. It’s soft and sensitive, but also tough and resilient, even self-healing. It’s both the barrier that protects us from infections and our most intimate connection with the outside world. Today’s guest, Zhenan Bao, has spent the last two decades reverse engineering the skin’s many remarkable properties in order to create wearable electronics that are just as soft, flexible, and versatile as the skin itself.Bao envisions a world where stick-on devices cou...
This week, we're diving into recent research that sheds light on a new form of brain plasticity involving changes in the insulation of nerve fibers — called myelin. It turns out that myelin plasticity is implicated in a number of serious conditions, from epilepsy to drug abuse and addiction.We're excited to bring back two previous guests on the show to share their insights on this previously unknown form of plasticity: Stanford psychiatry professor Rob Malenka (S1 E1 - Psychedelic...
The powerful new generation of AI tools that has come out over the past few years — DALL-E, ChatGPT, Claude, Gemini, and the rest — have blown away our old ideas about what AI can do and raised questions about what it means for computers to start acting... intelligent?This week, we ask what the rise of these systems might teach us about our own biological intelligence — and vice versa. What does modern neuroscience have to say about how AI could become as flexible, efficient, and resili...
At some point in our lives, we all struggle with memory — learning a new name, remembering that book you were reading just yesterday or that word on the tip of your tongue. So what can neuroscience teach us about why we remember, why we forget, and how we might even improve our memories? To answer this question, I spoke with neuroscientist Anthony Wagner, a memory expert in Stanford's Department of Psychology.Learn MoreWagner lab websiteRecent lab publicationsAnthony's new book: Brain Science...
Today, we're going to talk about how psychedelics alter our perception of reality and what that says about... reality! Welcome to part two of our conversation with Stanford anesthesiologist and psychedelics researcher Boris Heifets! Last time, we talked with Boris about the question of why psychedelics help people with mental health disorders. This week, we're going to dive into a different question, which is to explore how psychedelics work in the brain. How are they able to alter some...
Psychedelics are a hot topic in psychiatry today. They’re producing dramatic reversals for patients with severe depression, PTSD, and other mental health conditions. But scientists still have fundamental questions about why these drugs are so effective. For example, is the "trip" even necessary? Some think it is not and are working to design drugs with similar brain chemistry but no psychoactive effects — “Taking the trip out of the drug.” Others suspect that many of the benefits of psy...
This week on From Our Neurons to Yours, we're talking about the neuroscience of climate change with neuroeconomist Nik Sawe.If you follow the science or the news, you know how big of a risk climate change is. Storms, coastal flooding, heat waves, extinctions, mass migration — the list goes on. But — as you can probably also appreciate — it’s really hard to properly perceive that risk. It’s much easier to focus on today’s emergency, this week’s looming deadline, this quarter’s economic forecas...
This week we’re doing something a little different. My good friend Michael Osborne, who produces this show also has his own podcast, called Famous & Gravy – Life Lessons from Dead Celebrities.I recently guest-hosted an episode about one of my all time scientific and writerly heros, Oliver Sacks, which we're releasing for both our audiences. I hope you enjoy!---We've concluded Season 3 of From Our Neurons to Yours! Stay tuned for more conversations from the frontiers of neuroscience in Sea...
Today: the clocks in your body.We're talking again this week with Tony Wyss-Coray, the director of the Knight Initiative for Brain Resilience here at Wu Tsai Neuro. Last year, we spoke with Tony about the biological nature of the aging process. Scientists can now measure signs of aging in the blood, and can in some cases slow or reverse the aging process in the lab. We discussed how this biological age can be quite different from your chronological age, and why understanding why people a...
Today on the show, a new understanding of Parkinson's disease. Parkinson's disease is one of the most common neurodegenerative disorders — right after Alzheimer's disease. It's familiar to many as a movement disorder: people with the disease develop difficulties with voluntary control of their bodies. But the real story is much more complicated.This week, we speak with Kathleen Poston, a Stanford neurologist who is at the forefront of efforts to redefine Parkinson's disease and related disord...
This week on From Our Neurons to Yours, we sit down with Stanford neurobiologist Lisa Giocomo to explore the intersection of memory and navigation. This episode was inspired by the idea of memory palaces. The idea is simple: Take a place you're very familiar with, say the house you grew up in, and place information you want to remember in different locations within that space. When it's time to remember those things, you can mentally walk through that space and retrieve those items.This ancie...
In this episode of "From Our Neurons to Yours," we're taking a deep dive into the neuroscience of obsessive-compulsive disorder (OCD) and the recent discovery that the anesthetic ketamine can give patients a week-long "vacation" from the disorder after just one dose.Join us as we chat with Dr. Carolyn Rodriguez, a leading expert in the field, who led the first clinical trial of Ketamine for patients with OCD. She sheds light on what OCD truly is, breaking down the misconceptions and revealing...
Welcome to "From Our Neurons to Yours," from the Wu Tsai Neurosciences Institute at Stanford University. Each week, we bring you to the frontiers of brain science — to meet the scientists unlocking the mysteries of the mind and building the tools that will let us communicate better with our brains.This week, we're tackling a BIG question in neuroscience: why do we do what we do? Specifically, we're talking about dopamine, and why the common understanding of this molecule as a "pleasure ...
Imagine being trapped in your own body, unable to move or communicate effectively. This may seem like a nightmare, but it is a reality for many people living with brain or spinal cord injuries. Join us as we talk with Jaimie Henderson, a Stanford neurosurgeon leading groundbreaking research in brain-machine interfaces. Henderson shares how multiple types of brain implants are currently being developed to treat neurological disorders and restore communication for those who have lost the abilit...
Imagine an electrical storm in your brain, a power surge that passes through delicately wired neural circuits, making thousands of cells all activate at once. Depending on where it starts and where it travels in the brain, it could make your muscles seize up. It could create hallucinatory visions or imaginary sounds. It could evoke deep anxiety or a sense of holiness, or it could even make you lose consciousness. This kind of electrical storm is what we call a seizure. If your brain is prone ...